Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 628 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-communicable Disease Clear all

Conditions: Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Interventions: Artesunate ointment, Placebo ointment; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more

Conditions: Hepatitis C
Interventions: Eltrombopag, Antiviral therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: San Diego, California • New Haven, Connecticut • Honolulu, Hawaii + 3 more

Conditions: Uveitis
Interventions: Daclizumab (Zenapax); Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: acyclovir, acyclovir sodium, valacyclovir; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 6
States / cities: Duarte, California • Stanford, California • Omaha, Nebraska + 3 more

Conditions: Hepatitis C
Interventions: DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV; Drug
Lead sponsor: Timothy Morgan, MD; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Uveitis
Interventions: 0.59 mg Fluocinolone Acetonide implant; Drug
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Uveitis
Interventions: Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab; Drug
Lead sponsor: XOMA (US) LLC; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 51
States / cities: Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 48 more

Conditions: HIV Infection, Hepatitis C
Interventions: nelfinavir 1,250 mg twice daily, Zidovudine 300 mg twice daily, Lamivudine 150 mg twice daily; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Bakersfield, California • Miami, Florida • Shreveport, Louisiana + 1 more

Conditions: Chronic Hepatitis C Infection, Hepatitis C, Hepatitis C Virus
Interventions: ABT-450, ABT-333, ribavirin, ritonavir; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 8 more

Conditions: Cirrhosis, Chronic Hepatitis C, Hepatitis C, Hepatitis C, Chronic
Interventions: DUAL, QUAD; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Prostate Carcinoma, Advanced Renal Cell Carcinoma, Advanced Thyroid Gland Medullary Carcinoma, Advanced Triple-Negative Breast Carcinoma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, HIV Infection, Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Kaposi Sarcoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Differentiated Thyroid Gland Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Kaposi Sarcoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Medullary Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Recurrent Urothelial Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8
Interventions: Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • The Bronx, New York • Pittsburgh, Pennsylvania

Conditions: Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
Interventions: ATL-RIC, mRIC, allo HCT, RIC, GVHD prophylaxis, IOC; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2030
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: HIV Infections
Interventions: Calanolide A; Drug
Lead sponsor: Sarawak MediChem Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Miami, Florida • Vero Beach, Florida • Chicago, Illinois + 6 more

Conditions: Noninfectious Posterior Uveitis
Interventions: fluocinolone acetonide intravitreal implant, Fluocinolone acetonide 2.1mg; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Symptomatic COVID-19 Infection Laboratory-Confirmed, Waldenstrom Macroglobulinemia
Interventions: Ibrutinib, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Disease
Interventions: HAART regimen, 3TC or FTC monotherapy; Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 8 Years to 24 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: San Francisco, California • Washington D.C., District of Columbia • Jacksonville, Florida + 7 more

Conditions: Chronic Hepatitis C
Interventions: Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin; Drug
Lead sponsor: InterMune; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Bronchiectasis
Interventions: Ciprofloxacin (Cipro, BAYQ3939), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Little Rock, Arkansas • La Jolla, California • Denver, Colorado + 8 more

Conditions: Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Interventions: AP-PA02, Placebo; Biological · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 23
States / cities: Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more

Conditions: Gonorrhea
Interventions: zoliflodacin, ceftriaxone, azithromycin; Drug
Lead sponsor: Global Antibiotics Research and Development Partnership; Other
Eligibility: 12 Years and older
Enrollment: 1,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 2 more

Conditions: HIV Infections
Interventions: Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A, NefTat, AS02A Adjuvant, gp120W61D; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2003
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 9 more

Conditions: Surgical Site Infection
Interventions: Chlorhexidine Cloth; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Scleritis, Orbital Disease
Interventions: Rituximab; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Uveitis, Macular Edema
Interventions: Efalizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390

ANTI-TAC THERAPY FOR UVEITIS

Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus

Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment

Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment

An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment

Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy

CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)

Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Zoliflodacin in Uncomplicated Gonorrhoea

An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV

Chlorhexidine Cloths to Reduce Surgical Site Infection in Cesarean Deliveries

Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation

Efalizumab to Treat Uveitis